Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples

Abstract

Available evidence concerning the side effects experienced by bipolar disorder (BD) patients under naturalistic conditions has been poorly investigated. The aim of this study was therefore to investigate side effects related to major psychotropic drugs in two independent samples of BD patients naturalistically treated with mood stabilizers, antidepressants, antipsychotics and/or anxiolytics. Overall, 3654 patients from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) sample and 282 patients from the Clinical Outcome and Psycho-Education for Bipolar Disorder (COPE-BD) sample were included. The primary outcome measure was the influence of each class of psychotropic drugs under investigation on the emergence of any side effect, as measured with the monitoring form in the STEP-BD study and the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale in the COPE-BD study. Secondary outcome measures included the effects of such drugs on psychic, neurologic, autonomic and other side effects. Mood stabilizers and antipsychotics were associated with high rates of side effects in both samples. Furthermore, antipsychotics were specifically associated with psychic side effects, whereas mood stabilizers were specifically associated with neurologic side effects. Our results largely confirm in a naturalistic setting results previously observed in randomized controlled trials focusing on BD patients.

Keywords

Side effects bipolar disorder mood stabilizers antidepressants antipsychotics anxiolytics

Get full access to this article

View all access options for this article.

References

American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Washington, DC: American Psychiatric Association.

Baldessarini

Pompili

Tondo

(2006) Suicide in bipolar disorder: Risks and management. CNS Spectr 11: 465–471.

Bauer

(2002) A review of quantitative studies of adherence to mental health clinical practice guidelines. Harv Rev Psychiatry 10: 138–153.

Berk

(2003) Mood stabilizers and treatment adherence in bipolar disorder: Addressing adverse events. Ann Clin Psychiatry 15: 217–224.

Brooks

III Goldberg

Ketter

. (2011) Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: Findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry 72: 240–247.

Calabrese

Elhaj

Gajwani

. (2005) Clinical highlights in bipolar depression: Focus on atypical antipsychotics. J Clin Psychiatry 66: S26–S33.

Canas

Moller

(2010) Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: Safety and tolerability review. Expert Opin Drug Saf 9: 683–697.

Cohen

(1988) Statistical Power Analysis for the Behavioral Sciences. Hillsdale, New Jersey: Lawrence Erlbaum Associates.

Connolly

Thase

(2011) The clinical management of bipolar disorder: A review of evidence-based guidelines. Prim Care Companion CNS Disord 13. PCC.10r01097.

10.

De Fruyt

Deschepper

Audenaert

. (2012) Second generation antipsychotics in the treatment of bipolar depression: A systematic review and meta-analysis. J Psychopharmacol 26: 603–617.

11.

De Leon

Susce

Pan

. (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66: 15–27.

12.

Demyttenaere

Albert

Mesters

. (2005) What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J Clin Psychiatry 66: 859–863.

13.

Dennehy

Bauer

Perlis

. (2007) Concordance with treatment guidelines for bipolar disorder: Data from the systematic treatment enhancement program for bipolar disorder. Psychopharmacol Bull 40: 72–84.

14.

Depping

Komossa

Kissling

. (2010) Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev: CD008120.

15.

Fountoulakis

Kasper

Andreassen

. (2012) Efficacy of pharmacotherapy in bipolar disorder: A report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 262: S1–S48.

16.

Gallego

Nielsen

De Hert

. (2012) Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 11: 527–542.

17.

Gelenberg

Jefferson

(1995) Lithium tremor. J Clin Psychiatry 56: 283–287.

18.

Grandjean

Aubry

(2009) Lithium: updated human knowledge using an evidence-based approach: Part III: Clinical safety. CNS Drugs 23: 397–418.

19.

Guille

Sachs

Ghaemi

(2000) A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 61: 638–642.

20.

Hirschfeld

(2003) The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry 64: S15–S21.

21.

Hirschfeld

Calabrese

Weissman

. (2003) Screening for bipolar disorder in the community. J Clin Psychiatry 64: 53–59.

22.

Kessler

Berglund

Demler

. (2003) The epidemiology of major depressive disorder: Results from the national comorbidiy survey replication (NCS-R). JAMA 289: 3095–3105.

23.

Komossa

Depping

Gaudchau

. (2010) Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev: CD008121.

24.

Kumra

Oberstar

Sikich

. (2008) Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 34: 60–71.

25.

Lader

(1999) Some adverse effects of antipsychotics: Prevention and treatment. J Clin Psychiatry 60: S18–S21.

26.

Lin

Mok

Yatham

(2006) Polytherapy in bipolar disorder. CNS Drugs 20: 29–42.

27.

Lingjaerde

Ahlfors

Bech

. (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334: 1–100.

28.

MacQueen

Young

(2003) Cognitive effects of atypical antipsychotics: Focus on bipolar spectrum disorders. Bipolar Disord 5: S53–S61.

29.

Meltzer

Bobo

(2006) Interpreting the efficacy findings in the CATIE study: What clinicians should know. CNS Spectr 11: 14–24.

30.

Merikangas

Akiskal

Angst

. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64: 543–552.

31.

Miller

Yatham

Lam

(2001) Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry 62: 975–980.

32.

Nivoli

Colom

Murru

. (2011) New treatment guidelines for acute bipolar depression: A systematic review. J Affect Disord 129: 14–26.

33.

Nivoli

Murru

Goikolea

. (2012) New treatment guidelines for acute bipolar mania: A critical review. J Affect Disord 140: 125–141.

34.

Papakostas

(2010) The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry 71: e03.

35.

Rummel-Kluge

Komossa

Schwarz

. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophr Res 123: 225–233.

36.

Sachs

Guille

McMurrich

(2002) A clinical monitoring form for mood disorders. Bipolar Disord 4: 323–327.

37.

Sachs

Nierenberg

Calabrese

. (2007) Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356: 1711–1722.

38.

Sachs

Thase

Otto

. (2003) Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 53: 1028–1042.

39.

Sharma

(1999) Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry 38: 44–51.

40.

Sheehan

Lecrubier

Sheehan

. (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59: S22–S33;quiz 34–57.

41.

Solomon

Keitner

Ryan

. (1996) Polypharmacy in bipolar I disorder. Psychopharmacol Bull 32: 579–587.

42.

Souery

Zaninotto

Calati

. (2011) Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features. J Affect Disord 135: 241–250.

43.

Souery

Zaninotto

Calati

. (2012) Depression across mood disorders: Review and analysis in a clinical sample. Compr Psychiatry 53: 24–38.

44.

Ten Have

Vollebergh

Bijl

. (2002) Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): Results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord 68: 203–213.

45.

Uzun

Kozumplik

Jakovljevic

. (2010) Side effects of treatment with benzodiazepines. Psychiatr Danub 22: 90–93.

46.

Velligan

Weiden

Sajatovic

. (2009) The expert consensus guideline series: Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70: S1–S46; quiz 47–48.

47.

Watson

(1988) Intraindividual and interindividual analyses of positive and negative affect: Their relation to health complaints, perceived stress, and daily activities. J Pers Soc Psychol 54: 1020–1030.

48.

Zetin

Hoepner

Bjornson

(2006) Rational antidepressant selection: Applying evidence-based medicine to complex real-world patients. Psychopharmacol Bull 39: 38–104.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.30 MB